Single dose azithromycin versus ciprofloxacin for cholera in children: A randomized controlled trial
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To compare the clinical and bacteriological success of single dose treatment with azithromycin and ciprofloxacin in children with cholera.
Randomized, open labelled, clinical controlled trial.
Tertiary care hospital.
180 children between 2–12 years, having watery diarrhea for ≤24 hr and severe dehydration, who tested positive for Vibrio cholerae by hanging drop examination or culture of stool.
Main outcome measures
Clinical success (resolution of diarrhea within 24 hr) and bacteriological success (cessation of excretion of Vibrio cholerae by day 3). Secondary outcome variables included duration of diarrhea, duration of excretion of Vibrio cholerae in stool, fluid requirement, and proportion of children with clinical or bacteriological relapse.
The rate of clinical success was 94.5% (86/91) in children treated with Azithromycin and 70.7% (63/89) in those treated with Ciprofloxacin [RR (95% CI)=1.34 (1.16–1.54); P<0.001]. Bacteriological success was documented in 100% (91/91) children in Azithromycin group compared to 95.5% (85/89) in Ciprofloxacin group [RR (95% CI)=1.05 (1.00–1.10); P=0.06]. Patients treated with Azithromycin had a shorter duration of diarrhea [mean(SD) 54.6 (18.6) vs 71.5 (29.6) h; mean difference (95% CI) 16.9 (9.6–24.2); P<0.001] and lesser duration of excretion of Vibrio cholerae [mean(SD) 34.6 (16.3) vs 52.1 (29.2) h; mean difference (95% CI) 17.5 (0.2–24.7), P<0.001] in children treated with Azithromycin vs Ciprofloxacin. The amount of intravenous fluid requirement was significantly less among subjects who received Azithromycin as compared to those who received Ciprofloxacin [mean(SD) 4704.7(2188.4) vs 3491.1(1520.5) mL; Mean difference (95% CI) 1213(645.3–1781.9); P<0.001]. Proportion of children with bacteriological relapse was comparable in two groups [6.7% (6/89) vs 2.2% (2/91); RR (95% CI) 0.95 (0.89–1.01); P=0.16]. None of the children in either group had a clinical relapse.
Single dose azithromycin is superior to ciprofloxacin for treating cholera in children.
- Gupta, P., Ghai, O.P. Acute Diarrheal Diseases. In: Gupta, P., Ghai, O.P. eds. (2007) Textbook of Preventive and Social Medicine. CBS Publishers and Distributors, New Delhi, pp. 298-305
- WHO Guidance on Formulation of National Policy on the Control of Cholera. From http://www.who.int/topics/cholera/publications/WHO_CDD_SER_92_16/en. Accessed on January 12, 2007.
- Guidelines for Cholera Control. WHO, Geneva
- Emergence of a unique, multi-drug resistant strain of Vibrio cholerae O1 in Bangladesh. From: http://www.icddrb.org/images/hsb32_Eng-emergence.pdf. Accessed on August 20, 2006.
- Grady, R. (2003) Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 22: pp. 1128-1132 CrossRef
- Khan, W.A., Michael, L.B., Seas, C., Khan, E.H., Ronan, A., Dhar, U. (1996) Randomized controlled comparison of single dose ciprofloxacin and doxycycline for cholera caused by V. cholerae O1 or O139. Lancet 348: pp. 296-300 CrossRef
- Saha, D., Karim, M.M., Khan, W.A., Ahmed, S., Salam, M.A., Bennish, M.L. (2006) Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 354: pp. 2452-2462 CrossRef
- Saha, D., Khan, W.A., Karim, M.M., Chowdhury, H.R., Salam, M.A., Bennish, M.L. (2005) Single-dose ciprofloxacin versus 12-dose Erythromycin for childhood cholera: a randomized controlled trial. Lancet 366: pp. 1085-1093 CrossRef
- Garg, P., Chakraborty, S., Basu, I., Datta, S., Rajender, K., Bhattacharya, T. (2000) Expanding multiple antibiotic resistance among clinical strains of Vibrio cholerae isolated from 1992–97 in Calcutta, India. Epidemiol Infect 124: pp. 393-399 CrossRef
- Jesudason, M.V., Balaji, V., Thomson, C.J. (2002) Quinolone susceptibility of Vibrio cholerae O1 and O139 isolates from Vellore. Indian J Med Res 116: pp. 96-98
- Das, S., Goyal, R., Ramachandran, V.J., Gupta, S. (2005) Fluoroquinolone resistance in Vibrio cholerae O1: emergence of El Tor Inaba. Ann Trop Paediatr 25: pp. 211-212 CrossRef
- Jones, K., Felmingham, J., Ridgway, G. (1988) In vitro activity of Azithromycin (CP-62, 993), a novel macrolide, against enteric pathogens. Drugs Exp Clin Res 14: pp. 613-615
- Khan, W.A., Saha, D., Rahman, A., Salam, M.A., Bogaerts, J. (2002) Comparison of single-dose azithromycin and 12-dose 3-day erythromycin for childhood cholera: A randomized double-blind trial. Lancet 360: pp. 1722-1727 CrossRef
- Bhattacharya, M.K., Dutta, D., Ramamurthy, T., Sarkar, D., Singharoy, A., Bhattacharya, S.K. (2003) Azithromycin in the treatment of cholera in children. Acta Paediatr 92: pp. 676-678 CrossRef
- Kim JS. Determining sample size for testing equivalence. From: http://www.devicelink.com/mddi/archive/97/05/020.html. Accessed on February 23, 2008.
- Dasgupta, R. Social and Behavioral Sciences in Health. In: Gupta, P., Ghai, O.P. eds. (2007) Textbook of Preventive and Social Medicine. CBS Publishers and Distributors, New Delhi, pp. 622-644
- Pariija, S.C. Identification of Vibrio cholerae. In: Pariija, S.C. eds. (2007) Textbook of Practical Microbiology. Ahuja Publishing House, New Delhi, pp. 181-183
- Chattopadhyay, D.J., Sarkar, B.L., Ansari, M.Q., Chakrabarthi, B.K., Roy, M.K., Ghosh, A.N. (1993) New phage typing scheme for Vibrio cholerae O1 biotype ELTOR strains. J Clin Microbiol 31: pp. 1579-1585
- Khan, W.A., Seas, C., Dhar, U., Salam, M.A., Bennish, M.L. (1997) Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double blind, randomized controlled trial. Ann Intern Med 126: pp. 697-703
- Faruque, A.S.G., Alam, K., Malek, M.A., Khan, M.G.Y., Ahmed, S., Saha, D. (2007) Emergence of multi-drug resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr 25: pp. 241-245
- Garg, P., Sinha, S., Chakraborty, R., Bhattacharya, S.K., Nair, G.B., Ramamurthy, T. (2001) Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype ELTOR among hospitalized patients with cholera in Calcutta, India. Antimicrob Agents Chemother 45: pp. 1605-1610 CrossRef
- Krishna, B.V., Patil, A.B., Chandrasekhar, M.R. (2006) Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India. Trans R Soc Trop Med Hyg 100: pp. 224-226 CrossRef
- Single dose azithromycin versus ciprofloxacin for cholera in children: A randomized controlled trial
Volume 47, Issue 4 , pp 309-315
- Cover Date
- Print ISSN
- Additional Links
- Author Affiliations
- 1. Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, Delhi, India
- 3. 82-B, Saraswati Kunj, Plot No 25, IP Extension, Delhi, 110 092, India
- 2. Department of Microbiology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, Delhi, India